Meta-Analysis
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 352-367
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.352
Figure 4
Figure 4 Incidence of immune-related adverse events associated with anti-anti- programmed cell death receptor-1 (nivolumab) in case series. A: All grade; B: Severe grade.